Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-05-01
2007-05-01
Nickol, Gary (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C514S866000, C514S909000, C530S300000, C530S308000
Reexamination Certificate
active
10429522
ABSTRACT:
This invention relates the use of glucagon-like peptides such as GLP-1, a GLP-1 analog, or a GLP-1 derivative in methods and compositions for reducing body weight.
REFERENCES:
patent: 5118666 (1992-06-01), Habener
patent: 5120712 (1992-06-01), Habener
patent: 5512549 (1996-04-01), Chen et al.
patent: 5545618 (1996-08-01), Buckley et al.
patent: 5693609 (1997-12-01), Baker et al.
patent: 5762953 (1998-06-01), Venkateshwaran
patent: 6191102 (2001-02-01), DiMarchi et al.
patent: 6583111 (2003-06-01), DiMarchi et al.
patent: 658568 (1995-06-01), None
patent: 708179 (1996-04-01), None
patent: WO 91/11457 (1991-08-01), None
patent: WO 93/16105 (1993-08-01), None
patent: WO 93/18786 (1993-09-01), None
patent: WO 93/25579 (1993-12-01), None
patent: WO 95/05848 (1995-03-01), None
patent: WO 95/31214 (1995-11-01), None
patent: WO 96/05309 (1996-02-01), None
patent: WO 96/25487 (1996-02-01), None
patent: WO 96/29342 (1996-09-01), None
patent: WO 97/31943 (1997-09-01), None
patent: WO 98/05351 (1998-02-01), None
patent: WO 98/08871 (1998-03-01), None
patent: WO 98/08872 (1998-03-01), None
patent: WO 98/20895 (1998-05-01), None
Aderlhorst et. al. J. Biol. Chem. 269:6275-6278, 1994.
David et al., J. Biol. Chem. vol. 268, 17247-17252, 1993.
Barbash, G. I., et al., “Significance of Diabetes Mellitus in Patients with Acute Myocardial Infarction Receiving Thrombolytic Therapy,” (1993) JACC 22 (3) :707-713.
Begliner, C., Effect of Cholecystokinin on Gastric Motility in Humans, (1994) AnnNYAcad. Sci. 713:219-225.
Bevilacqua, S., et al., “Acute Elevation of Free Fatty Acid Levels Leads to Hepatic Insulin Resistance in Obese Subjects,” (1987) Metabolism 36(5) :502-506.
Bevilacqua, S., et al., “Operation of Randle's Cycle in Patients With NIDDM,” (1990)Diabetes39:383-389.
Billington, C.J. and Levine, A.S., “Appetite regulation: Shedding New Light on Obesity,” (1996)Current Biology6(8):920-923.
Bing, C., et al., “the central regulation of energy homoeostasis: roles of neuropeptide Y and other brain peptides,” (1996)Biochemical Society Transactions24:559-565.
Bonadonna, R. C., et al., “Dose-dependent effect of insulin on plasma free fatty acid turnover and oxidation in humans,” (1990)American Physiological Society:E736-E750.
Bonadonna, R. C., et al., “Time dependence of the interaction between lipid and glucose in humans,” (1989)American Physiological Society: E49-E56.
Broderick, C. L., et al., “Abstract of Effect of sub-chronic administration of GLIP(7-37)OH on beta cell failure in Zucker diabetic rats,” (1995)Dibetologia38 (suppl.):Al71.
Bullock, B.P., et al., “Tissue Distribution of Messenger Ribonucleic Acid Encoding the Rat Glucagon-Like Peptide-1 Receptor,” (1996)—Endocrinology 137(7):2968-2978.
Chen, C.H. and Rogers, R.C., Central Inhibitory Action of Peptide YY on Gastric Motility in Rats, (1995)Am. J. Physiol.269(4 Pt2):R787-792.
Chen, J.D., et al., “Inhibitory Effects of Chloecytokinin on Postprandial Gastric Myoelectrocal Activity,” (1995)Dig. Dis. Sci.40(12): 2614-2622.
Chen, C.H. and Rogers, R.C., “PYY and NPY: Control of Gastric Motility Via Action on Y1 and Y2 Receptors in the DVC,” (1997)NeurogastroenterolMotil 9(2): 109-116.
Coskun, T., et al., “Pathways mediating CRF-induced Inhibition of gastric Emptying in Rats,” (1997) Regul. Pept. 69(3):113-130.
Davi, G., et al., “Thromboxane biosynthesis and platelet function in Type II diabetes mellitus,” (1990)The New England Journal of Medicine,322 (25):1769-1774.
Dhanvantari, S., et al., “Role of Prohormone Convertases in the Tissue-Specific Processing of Proglucagon,” (1996)Molecular Endocrinology10(4):342-355.
Doberne, L., et al., “Enhanced Glucose Utilization During Prolonged Glucose Clamp Studies,” (1981)Diabetes30:829-835.
Ferrannini, E., et al. “Effect of Fatty Acids on Glucose Production and Utilization in Man,” (1983)J. Clin. Invest.72 :1737-1747.
Fehmann, H., et al., “Glucagon-like peptide-1 (7-37) / (7-36) amide is a new incretin,” (1992)Molecular and Cellular Endocrinology85:C39-C44.
Frayn, K.N., I Hormonal control of metabolism in trauma and sepsis, (1986)Clinical Endocrinology24:577-599.
Fuller, J. H., “Mortality trends and causes of death in diabetic patients,” (1993) Diabete &Metabolisme19:96-99.
Galuska, D., et al., “Effects of non-esterified fatty acids on insulin-stimulated glucose transport in isolated skeletal muscle from patients with type 2 (non-insulin-dependent) diabetes mellitus,” (1994) Acta Diabetol 31:169-172.
Garvey, W. T., “Glucose Transport and NIDDM,” (1992)Diabetes Care15(3):396-417.
Gutniak, M. et al., Antidiabetogenic Effects of Glucagon-Like Peptide-1(7-36) Amide in Normal Subjects and Patients with Diabetes Mellitus:New England Journal of Medicine, vol. 326, No. 20, pp. 1316-1322, 1992.
Gutniak, M. K., et al., Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide l Abolishes Postprandial Glycemia in NIDDM, (1994)Diabetes Care17(9):1039-1044.
Hamann, A. And Matthaei, S., I Regulation of energy balance by leptin, (1996)Exp. Clin. Endocrinal Diabetes104:293-300.
Hamilton, B.S., “A new role for a fat actor,” (1996)Nature Medicine2(3):272-273.
Higham, A., et al., “Relation Between Cholecystokinin and Antral Innervation in the Control of Gastric Emptying in the Rat” (1997) Gut 41(1):24-32.
International Search Report.
Jin, H., et al., “Secretin: A Physiological Regulator of Gastric Emptying and Acid Output in Dogs,” (1994) Am. J. Physiol. 267(4 Pt 1) :G702-708.
Juntti-Berggren, L. et al., “Abstract of The antidiabetogenic effect of GLP-1 is maintained during a seven day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients,” :1-27.
Lambert, P. D.,et al, “A role for GLP-1(7-36)NH2 in the Central Control of Feeding Behaviour”,Digestion, 54:360-361, 1994.
Larsen, J., et al., “One-Week Continuous Infusion of GLP-1(7-37) Improves the Glycaemic Control of NIDDM,” (1996)Diabet. 45(Supplement 2) :223A. Larsen, J., et al., abstract of “One-Week Continuous Infusion of GLP-1(7-37) Improves the Glycoemic Control in NIDDM,” (1996)Diabetes Abstract Book45 (Supp. 2):860.
Lu, Y. And Owyang, C. “Secretin at Physiological Doses Inhibits Gastric Motility Via a Vagal Afferent Pathway,” (1995)Am. J. Physiol.268 (6 Pt 1):G1012-6.
M. Navarro, et al., Changes in Food Intake Induced by GLP-1(7-36) amide in the Rat,Abstracts of the 15th International Diabetes Federation Congress, Nov. 6-11, 1994 Kobe, poster presentation 11A5PP1295.
M. Navarro, et al., “Colocalization of Glucagon-Like Peptide-1 (GLP-1) Receptors, Glucose Transporter GLUT-2, and Glucokinase mRNAs in Rat Hypothalamic Cells: Evidence for a Role of GLP-1 Receptor Agonists as an Inhibitory Signal for Food and Water Intake”,Journal of Neurochemistry, vol. 67, No. 5, p. 1982-1991, 1996.
Nightingale, J.M., et al., “Gastrointestinal hormones in Short Bowel Syndrome. Peptide YY May be the ‘Colonic Brake’ to Gastric Emptying,” (1996) Gut 39(2):267-272.
Raybould, H.E. And Holtzer, H., “Secretin Inhibits Gastirc Emptying in Rats Via a Capsaicin-Sensitive Vagal Afferent Pathway,” (1993)Eur. J.—Pharmacol. 250(1):165-167.
Schick,R., et al., “Glucagon-like peptide 1—a novel brain peptide involved in feeding regulation”,Obesity in Europe, Chapter 53, pp. 363-367, 1993.
Schwizer, W., et al. “Role of Cholecystokinin in the Regulation of Liquid Gastric Emptying and Gastric Motility in Humans: Studies with the CCK Antagonist Loxiglumide,” (1997) Gut 41(4):500-504.
Serradas, P., et al., Abstract GLP-1 confers glucose sensitivity to previously glucose-resistant B cells in a rat model of non insulin dependent diabetes, Diabetologia (1995).
Takahashi, T. And Owyang,
DiMarchi Richard
Efendic Suad
Chandra Gyan
Cox Gregory A.
Eli Lilly and Company
Nickol Gary
Stewart Mark J.
LandOfFree
Use of GLP-1 analogs and derivatives administered... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of GLP-1 analogs and derivatives administered..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of GLP-1 analogs and derivatives administered... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3811291